What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV2?

The first SARS-CoV2 vaccine(s) will likely be licensed based on neutralizing antibodies in Phase 2 trials, but there are significant concerns about using antibody response in coronavirus infections as a sole metric of protective immunity. Antibody response is often a poor marker of prior coronavirus...

Full description

Autores:

Tipo de recurso:

Article of investigation

Fecha de publicación:

2020

Institución:

Universidad de Bogotá Jorge Tadeo Lozano

Repositorio:

Expeditio: repositorio UTadeo

Idioma:

eng

OAI Identifier:

oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/12701

Acceso en línea:

https://doi.org/10.1016/j.jvacx.2020.100076
http://hdl.handle.net/20.500.12010/12701

Palabra clave:

SARS-CoV-2
SARS
COVID-19
Protective immunity
T-cells
CD8 T-cells
Antibodies
T cell lifespan
Durable immunity
Antibody-dependent enhancement
T-cell epitopes
Vaccines
Yellow Fever Vaccine
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus

Rights

License

Abierto (Texto Completo)